Analysts Change Price Targets on These Healthcare Stocks in December
Wall St. Watchdog reveals information about companies for which stock analysts reiterated ratings in the Healthcare sector for the week ending December 9th, 2011.
- Regeneron Pharms (NASDAQ:REGN): Brean Murray reiterated its rating of Buy for this company and changed its price target from $78 to $67 on Dec 5th. The shares recently traded at $53.04, down $2.02, or 3.67% since the analyst’s rating. About the company: Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. Get the most recent company news and stock data here >>
- Questcor Pharma (NASDAQ:QCOR): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $45 to $53 on Dec 8th. The shares recently traded at $44.03, up $1.52, or 3.58% since the analyst’s rating. About the company: Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company’s primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions. Get the most recent company news and stock data here >>
(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>